文献速递产科母胎医学

普伐他汀用于子痫前期高危孕妇的随机试点临床试验

A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.
PubMed 文献 · Am J Obstet Gynecol · 2021-05-24

这项多中心、盲法、安慰剂对照的随机试点试验纳入有早发型子痫前期病史的孕妇,比较每日20mg普伐他汀与安慰剂的安全性及药代动力学。结果显示两组不良事件、先天畸形及母胎血液化学指标无显著差异,普伐他汀组妊娠及新生儿结局更有利;研究支持开展更大规模试验评估其预防子痫前期的疗效,但目前孕期使用仍属研究性。

要点

  • 普伐他汀20mg组与安慰剂组不良事件、先天畸形及母胎血液化学指标无显著差异。
  • 普伐他汀组妊娠及新生儿结局更有利,所有新生儿听力筛查通过。
  • 孕期使用普伐他汀仍属研究性,需更大规模试验验证预防子痫前期的疗效。

核心结论

  • 本研究证实普伐他汀在高危子痫前期孕妇中总体安全且妊娠结局有利。
  • 有利的风险-获益分析支持开展更大规模临床试验评估普伐他汀预防子痫前期的疗效。
  • 在此之前,孕期使用普伐他汀仍属研究性。

研究设计与样本

  • 多中心、盲法、安慰剂对照、随机试点试验,纳入单胎、无畸形、子痫前期高危孕妇。
  • 孕妇在孕12+0至16+6周被分配至每日口服普伐他汀20mg组或安慰剂组,直至分娩。
  • 共10名普伐他汀组和10名安慰剂组孕妇完成试验。
  • 在孕中晚期及产后4-6个月进行稳态普伐他汀药代动力学研究。

主要发现

  • 两组不良事件、严重不良事件、先天畸形及母胎血液化学指标无显著差异。
  • 最常见副作用为头痛,其次为胃灼热和肌肉骨骼疼痛。
  • 分娩时多数脐带和母体样本中普伐他汀浓度低于检测定量下限。
  • 普伐他汀组妊娠及新生儿结局更有利,所有新生儿通过脑干听觉诱发电位或类似听力筛查。
  • 每日20mg剂量下平均最大浓度和曲线下面积较每日10mg剂量高2倍以上,但表观口服清除率、半衰期和达峰时间相似。

关键数值与推荐

  • 普伐他汀20mg组与安慰剂组在不良事件、先天畸形及母胎血液化学指标上无显著差异。
  • 每日20mg普伐他汀的平均最大浓度和曲线下面积较每日10mg剂量高2倍以上。
  • 表观口服清除率、半衰期和达峰时间在20mg与10mg剂量间相似,符合线性、剂量非依赖性药代动力学。

临床怎么用

  • 当前证据不支持孕期常规使用普伐他汀预防子痫前期,应仅在研究背景下使用。
  • 对子痫前期高危孕妇使用普伐他汀需充分告知其研究性及风险-获益。
  • 监测母胎安全性指标及不良事件,尤其是头痛、胃灼热和肌肉骨骼疼痛。

局限性

  • 本研究为试点试验,样本量小(每组10例完成),无法评估疗效。
  • 研究仅纳入有早发型子痫前期病史的单胎孕妇,结果外推受限。
  • 原文未报告主要结局的统计学比较结果及置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preeclampsia remains a major cause of maternal and neonatal morbidity and mortality. Biologic plausibility, compelling preliminary data, and a pilot clinical trial support the safety and utility of pravastatin for the prevention of preeclampsia. OBJECTIVE: We previously reported the results of a phase I clinical trial using a low dose (10 mg) of pravastatin in high-risk pregnant women. Here, we report a follow-up, randomized trial of 20 mg pravastatin versus placebo among pregnant women with previous preeclampsia who required delivery before 34+6 weeks' gestation with the objective of evaluating the safety and pharmacokinetic parameters of pravastatin. STUDY DESIGN: This was a pilot, multicenter, blinded, placebo-controlled, randomized trial of women with singleton, nonanomalous pregnancies at high risk for preeclampsia. Women between 12+0 and 16+6 weeks of gestation were assigned to receive a daily pravastatin dose of 20 mg or placebo orally until delivery. In addition, steady-state pravastatin pharmacokinetic studies were conducted in the second and third trimesters of pregnancy and at 4 to 6 months postpartum. Primary outcomes included maternal-fetal safety and pharmacokinetic parameters of pravastatin during pregnancy. Secondary outcomes included maternal and umbilical cord blood chemistries and maternal and neonatal outcomes, including rates of preeclampsia and preterm delivery, gestational age at delivery, and birthweight. RESULTS: Of note, 10 women assigned to receive pravastatin and 10 assigned to receive the placebo completed the trial. No significant differences were observed between the 2 groups in the rates of adverse or serious adverse events, congenital anomalies, or maternal and umbilical cord blood chemistries. Headache followed by heartburn and musculoskeletal pain were the most common side effects. We report the pravastatin pharmacokinetic parameters including pravastatin area under the curve (total drug exposure over a dosing interval), apparent oral clearance, half-life, and others during pregnancy and compare it with those values measured during the postpartum period. In the majority of the umbilical cord and maternal samples at the time of delivery, pravastatin concentrations were below the limit of quantification of the assay. The pregnancy and neonatal outcomes were more favorable in the pravastatin group. All newborns passed their brainstem auditory evoked response potential or similar hearing screening tests. The average maximum concentration and area under the curve values were more than 2-fold higher following a daily 20 mg dose compared with a 10 mg daily pravastatin dose, but the apparent oral clearance, half-life, and time to reach maximum concentration were similar, which is consistent with the previously reported linear, dose-independent pharmacokinetics of pravastatin in nonpregnant subjects. CONCLUSION: This study confirmed the overall safety and favorable pregnancy outcomes for pravastatin in women at high risk for preeclampsia. This favorable risk-benefit analysis justifies a larger clinical trial to evaluate the efficacy of pravastatin for the prevention of preeclampsia. Until then, pravastatin use during pregnancy remains investigational.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Costantine MM, West H, Wisner KL, et al. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol. 2021. PMID: 34033812. doi:10.1016/j.ajog.2021.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。